Breast cancer research company files IPO

Nearly one year to the day after it pulled its planned initial public offering, Seattle, Washington-based Atossa Genetics officially registered with the SEC with plans to offer 1 million shares at $5 to $7.

GenomeWeb reports Atossa, a biotech that develops diagnostic tests for breast cancer, reneged its IPO on February 15 without citing an specific reason.

However, this current offering could command a market value of $106 million. It plans to use the funds to expand its cytology and molecular diagnostics laboratory - The National Reference Laboratory for Breast Health - as well as to hire and train sales and marketing staff, continue research and development, support internal research and for general corporate purposes.

Healthcare companies in Boston interested in breast cancer research may want to take a closer look at Atossa's developments. It has already begun diagnostic tests for breast cancer - with hopes of offering two more by 2013 - and has a proprietary treatment for pre-cancerous breast changes that could begin preclinical studies this year.

One of the highest-ranked Boston accounting firms, KLR boasts 160 team members across the East Coast. Because of its expansive reach, employees are able to specialize in support for healthcare-based companies, including practice management consulting, corporate compliance assistance and business valuation services.